Home > Haematology > EHA 2021 > Haemoglobinopathies > Personalising treatment for sickle cell disease

Personalising treatment for sickle cell disease

Presented By
Dr Erfan Nur, Amsterdam University Medical Center, the Netherlands
Conference
EHA 2021
Sickle cell disease (SCD) includes various inherited red blood cell disorders, calling for a variety of treatment approaches. To achieve the optimal treatment for each SCD patient, physicians should consider patient-related factors in combination with available treatment options. Dr Erfan Nur (Amsterdam University Medical Center, the Netherlands) discussed personalised treatment options and their importance for patients with SCD [1]. Each SCD patient has a unique set of factors to consider in the treatment decision process: genotype (e.g. haemoglobin [Hb]SS, HbSC, HbSβ0, HbSβ+), disease burden (relative contribution of pathophysiologies: vaso-occlusion, haemolytic anaemia), complications (e.g. acute coronary syndrome, stroke, splenic sequestration), treatment factors (e.g. efficacy, side effects, availability, clinical trial eligibility), care network (level of access), and impact on daily and social life. Before 2017, treatmen...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on